The American Cancer Society estimates that in 2023, approximately 20,000 new cases of ovarian cancer will be diagnosed, and more that 13,000 women will tragically succumb to this devastating disease. Early detection is crucial for improving survival rates, yet ovarian cancer is often diagnosed at advanced stage due to subtle symptoms and a lack of effective screening methods. To address this critical need, we are collaborating with expert clinicians to discover novel blood-based biomarkers. Our goal is to develop innovative diagnostic tools that can identify ovarian cancer at an early stage, significantly increasing the chances of successful treatment and survival.
Early Detection of Ovarian Cancer
Novel blood-based biomarker discovery to improve women's health
Join us as we reimagine women’s health
We’re seeking passionate supporters to help advance our groundbreaking research.
Project Stage
Brigham-Wyss Diagnostics Accelerator
Team
Daniel W. Cramer
Join us as we reimagine women’s health
We’re seeking passionate supporters to help advance our groundbreaking research.
Join us as we reimagine women’s health
We’re seeking passionate supporters to help advance our groundbreaking research.